Navigation Links
Hemostatic drug less effective than originally predicted
Date:11/15/2010

The use of recombinant activated factor 7 (rFVIIa) a drug used to treat bleeding in hemophiliacs in patients without hemophilia is not recommended because of the potential for adverse events, found a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100408.pdf.

Recombinant activated factor 7 is a hemostatic agent licensed for the treatment of bleeding in hemophilia patients. It is also used "off-label" for the prevention and treatment of bleeding in patients without hemophilia including patients undergoing surgery, liver transplants and other procedures.

The use of rFVIIa in people without hemophilia appears to be common. For example, out of more than 2700 cases in the Australian and New Zealand Hemostasis Registry that use rFVIIa, only 1% had a diagnosis of hemophilia.

This systematic review was conducted to analyze the effectiveness and risks of rFVIIa in patients without hemophilia and to assess the implications of these results for future research.

"Physicians must believe that 'off-label' use is effective and outweighs risks," write Dr. Yulia Lin, Sunnybrook Health Sciences Centre and coauthors. "However, randomized controlled trials (RCTs) evaluating rFVIIa have raised concerns about adverse effects, particularly thromboembolic events (blood clots)."

The review, which looked at 14 prophylactic use RCTs including 1137 patients and 12 therapeutic use RCTs with 2538 patients, found uncertainty about the benefits and harms of this therapy.

"Clinically significant benefits of rFVIIa as a more general hemostatic drug (outside of hemophilia) remain unproven," conclude the authors. "This systematic review has not shown a consistent benefit of off-label rFVIIa use in the therapeutic setting and (at best) only modest benefits in the prophylactic setting. Given the potential risks, it cannot be recommended and in most cases, its use should be restricted to a clinical trial."


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Related medicine news :

1. Hemostatic powder stops bleeding ulcers: Doctor
2. New Malaria Drug Proves Effective in Study of African Children
3. 5-year results show keyhole bowel cancer surgery is safe and effective
4. New lymphoma therapy may be more effective with fewer side effects
5. Diverse surgeons initiative effectively increases underrepresented minorities in academic surgery
6. Gene Mutations May Blunt Plavixs Effectiveness, Study Finds
7. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
8. Parent-only treatment may be equally effective for children who are obese
9. Home Monitoring of Blood-Thinner Use Appears Effective
10. Conventional, annual Pap smear cost-effective follow-up after cervical lesion treatment
11. Proton therapy safe, effective for early-stage lung cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... Aliso Viejo, California (PRWEB) , ... January 15, 2017 , ... ... create a stylistic slideshow with complete customization and ease," said Christina Austin - CEO ... variety of controls so that users can edit the style and animation of their ...
(Date:1/15/2017)... ... January 15, 2017 , ... The JPR ... pleased to announce that it will be assisting HackensackUMC Mountainside with its public ... Ridge townships, servicing all surrounding towns. The firm will be working closely with ...
(Date:1/14/2017)... ... ... Volume 3 is a self animating masking transition which allows users to reveal any object ... Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 provides FCPX ... the next. , To use “Cut-Out First” presets, choose a video clip and ...
(Date:1/13/2017)... , ... January 13, 2017 , ... KOAMTAC ®, ... will be showcasing the next generation companion scanner and data collector at the National ... KDC270 has been created as an answer to the market’s need for more compact ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth are about as ... brush their teeth. Sadly, most dental hygiene products in the market contain chemical ingredients ... these people, continuing their daily oral care routine to keep their teeth white and ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... , January 13, 2017 Constant research ... AIDS will collectively contribute to the demand for western blotting ... a value of US$ 551.0 Mn by 2016 end. Developing ... the most lucrative markets for western blotting, whereas ... globally. ...
(Date:1/13/2017)... YORK , January 13, 2017 ... equities to see how they have fared at yesterday,s ... ), Galena Biopharma Inc. (NASDAQ: GALE ), ... These companies harness cellular and biomolecular processes to develop ... reduce our environmental footprint, feed the hungry, use less ...
Breaking Medicine Technology: